Bridgewater Associates LP Sells 35,957 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Bridgewater Associates LP cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 71.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,397 shares of the medical research company's stock after selling 35,957 shares during the quarter. Bridgewater Associates LP's holdings in NeoGenomics were worth $237,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NEO. SBI Securities Co. Ltd. purchased a new stake in shares of NeoGenomics in the fourth quarter worth $26,000. Versant Capital Management Inc increased its stake in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after acquiring an additional 1,142 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of NeoGenomics by 788.7% in the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after acquiring an additional 3,289 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after acquiring an additional 2,787 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of NeoGenomics by 33.2% during the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after purchasing an additional 1,103 shares in the last quarter. Institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NEO shares. Benchmark lowered shares of NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler cut their target price on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group reduced their target price on NeoGenomics from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Needham & Company LLC dropped their price target on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Finally, Bank of America reduced their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $19.30.

NeoGenomics Trading Up 1.8 %

Shares of NASDAQ:NEO traded up $0.18 during trading on Friday, reaching $10.27. 1,432,237 shares of the company traded hands, compared to its average volume of 966,356. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 52-week low of $8.05 and a 52-week high of $19.12. The business's fifty day moving average is $9.80 and its 200-day moving average is $13.47. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -16.56 and a beta of 1.41.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. As a group, analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.